Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

The dark sides of capillary morphogenesis gene 2.

Deuquet J, Lausch E, Superti-Furga A, van der Goot FG.

EMBO J. 2012 Jan 4;31(1):3-13. doi: 10.1038/emboj.2011.442. Epub 2011 Dec 6. Review.

2.

Characterization of the interaction between anthrax toxin and its cellular receptors.

Liu S, Leung HJ, Leppla SH.

Cell Microbiol. 2007 Apr;9(4):977-87.

3.

Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo.

Liu S, Crown D, Miller-Randolph S, Moayeri M, Wang H, Hu H, Morley T, Leppla SH.

Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12424-9. doi: 10.1073/pnas.0905409106. Epub 2009 Jul 15.

4.

The receptors that mediate the direct lethality of anthrax toxin.

Liu S, Zhang Y, Hoover B, Leppla SH.

Toxins (Basel). 2012 Dec 27;5(1):1-8. doi: 10.3390/toxins5010001.

5.

Interactions between anthrax toxin receptors and protective antigen.

Scobie HM, Young JA.

Curr Opin Microbiol. 2005 Feb;8(1):106-12. Review.

PMID:
15694864
6.

Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor.

Lacy DB, Wigelsworth DJ, Scobie HM, Young JA, Collier RJ.

Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6367-72. Epub 2004 Apr 12.

7.

Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice.

Liu S, Miller-Randolph S, Crown D, Moayeri M, Sastalla I, Okugawa S, Leppla SH.

Cell Host Microbe. 2010 Nov 18;8(5):455-62. doi: 10.1016/j.chom.2010.10.004.

8.

Hyaline fibromatosis syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors.

Deuquet J, Lausch E, Guex N, Abrami L, Salvi S, Lakkaraju A, Ramirez MC, Martignetti JA, Rokicki D, Bonafe L, Superti-Furga A, van der Goot FG.

EMBO Mol Med. 2011 Apr;3(4):208-21. doi: 10.1002/emmm.201100124. Epub 2011 Feb 15.

9.

Hyaline fibromatosis syndrome with mutation c.1074delT of the CMG2 gene: a case report.

Jaouad IC, Guaoua S, Hajjioui A, Sefiani A.

J Med Case Rep. 2014 Sep 3;8:291. doi: 10.1186/1752-1947-8-291.

10.

Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.

Scobie HM, Rainey GJ, Bradley KA, Young JA.

Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5170-4. Epub 2003 Apr 16.

11.

Anthrax lethal and edema toxins in anthrax pathogenesis.

Liu S, Moayeri M, Leppla SH.

Trends Microbiol. 2014 Jun;22(6):317-25. doi: 10.1016/j.tim.2014.02.012. Epub 2014 Mar 27. Review.

12.

A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.

Rogers MS, Cryan LM, Habeshian KA, Bazinet L, Caldwell TP, Ackroyd PC, Christensen KA.

PLoS One. 2012;7(6):e39911. doi: 10.1371/journal.pone.0039911. Epub 2012 Jun 29.

13.

Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis.

Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, Kayserili H, Yuksel-Apak M, Paller AS, Norton K, Teebi AS, Grum-Tokars V, Martin GS, Davis GE, Glucksman MJ, Martignetti JA.

Am J Hum Genet. 2003 Oct;73(4):957-66. Epub 2003 Sep 12.

14.

Crystal structure of a complex between anthrax toxin and its host cell receptor.

Santelli E, Bankston LA, Leppla SH, Liddington RC.

Nature. 2004 Aug 19;430(7002):905-8. Epub 2004 Jul 4.

15.

Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors.

Cai C, Che J, Xu L, Guo Q, Kong Y, Fu L, Xu J, Cheng Y, Chen W.

PLoS One. 2011;6(6):e20646. doi: 10.1371/journal.pone.0020646. Epub 2011 Jun 2.

16.

Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor.

Li L, Guo Q, Liu J, Zhang J, Yin Y, Dong D, Fu L, Xu J, Chen W.

Toxins (Basel). 2016 Jan 20;8(1). pii: E28. doi: 10.3390/toxins8010028.

17.

Improving the anti-toxin abilities of the CMG2-Fc fusion protein with the aid of computational design.

Xi Y, Wu X, Gao L, Shao Y, Peng H, Chen H, Chen H, Hu X, Yue J.

PLoS One. 2014 Aug 7;9(8):e104674. doi: 10.1371/journal.pone.0104674. eCollection 2014.

18.

Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.

Chen KH, Liu S, Bankston LA, Liddington RC, Leppla SH.

J Biol Chem. 2007 Mar 30;282(13):9834-45. Epub 2007 Jan 24.

19.

Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis.

Jeong SY, Martchenko M, Cohen SN.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):E4007-15. doi: 10.1073/pnas.1316852110. Epub 2013 Oct 1.

20.

Receptor-specific requirements for anthrax toxin delivery into cells.

Rainey GJ, Wigelsworth DJ, Ryan PL, Scobie HM, Collier RJ, Young JA.

Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13278-83. Epub 2005 Sep 1.

Supplemental Content

Support Center